Upgrade to SI Premium - Free Trial

Immuneering Corporation (IMRX)

4.27 -0.21 (4.69%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (8/12/26)

Latest Headlines

Mizuho defends Immuneering Corporation (IMRX), 'recommend being opportunistic on IMRX' June 2, 2026 6:43 AM - StreetInsider Form 8-K Immuneering Corp For: Jun 01 June 1, 2026 4:52 PM - SEC Filing Oppenheimer Reiterates Outperform Rating on Immuneering Corporation (IMRX) Following Data June 1, 2026 9:59 AM - StreetInsider Immuneering reports 17.3-month survival data for pancreatic cancer drug June 1, 2026 7:31 AM - StreetInsider Immuneering Presents Compelling 17.3-Month Median Overall Survival and Favorable Tolerability with Atebimetinib + Chemotherapy in First-Line Pancreatic Cancer Patients at ASCO June 1, 2026 7:30 AM - StreetInsider Immuneering reports 17.3-month survival in pancreatic cancer trial May 21, 2026 5:02 PM - StreetInsider Immuneering Reports 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated with Atebimetinib Plus Chemotherapy May 21, 2026 5:00 PM - Globe NewsWire Form 10-Q Immuneering Corp For: Mar 31 May 15, 2026 7:52 AM - SEC Filing Form 8-K Immuneering Corp For: May 15 May 15, 2026 7:44 AM - SEC Filing Immuneering reports Q1 2026 financial results and clinical updates May 15, 2026 7:35 AM - StreetInsider Immuneering Reports First Quarter 2026 Financial Results and Provides Business Updates May 15, 2026 7:35 AM - Globe NewsWire Immuneering to Present New Survival Data from First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP in an Oral Presentation at the 2026 ASCO Annual Meeting April 21, 2026 4:05 PM - StreetInsider Form DEFA14A Immuneering Corp April 20, 2026 4:16 PM - SEC Filing Form DEF 14A Immuneering Corp For: Apr 20 April 20, 2026 4:10 PM - SEC Filing Immuneering presents genetic data supporting atebimetinib durability April 20, 2026 9:01 AM - StreetInsider Immuneering Presents Genetic Data at AACR Annual Meeting Demonstrating Mechanism to Improve Durability and Survival, Supporting Use of Atebimetinib in First-Line Pancreatic Cancer and Beyond April 20, 2026 9:00 AM - StreetInsider Immuneering to Present at the 25th Annual Needham Virtual Healthcare Conference April 6, 2026 4:05 PM - StreetInsider Form 4 Immuneering Corp For: Mar 13 Filed by: Neufeld Leah R March 17, 2026 4:47 PM - SEC Filing Immuneering to Present Molecular Data at 2026 AACR Annual Meeting from Atebimetinib-Treated Patients, Highlighting Mechanism Designed to Improve Durability and Survival March 17, 2026 4:35 PM - StreetInsider Immuneering Corporation (IMRX) PT Lowered to $12; Piper Sandler: 'We Remain Buyers' March 9, 2026 8:05 AM - StreetInsider Full Article List